Peptic ulcer disease

The Lancet

Volumn 374, Issue 9699, 2009, Pages 1449-1461

  Malfertheiner, Peter ^a   Chan, Francis KL ^b   McColl, Kenneth EL ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; BISMUTH SALT; CLARITHROMYCIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; METRONIDAZOLE; MISOPROSTOL; MOXIFLOXACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; RIFABUTIN; SUCRALFATE; TETRACYCLINE; TINIDAZOLE;

ANTIBACTERIAL ACTIVITY; BIOPSY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG MECHANISM; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; EPIGASTRIC PAIN; ERADICATION THERAPY; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LOW DRUG DOSE; MONOTHERAPY; PATHOGENESIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; STOMACH ULCER; TREATMENT DURATION; TREATMENT PLANNING; UREA BREATH TEST; ZOLLINGER ELLISON SYNDROME;

EID: 70350128035     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60938-7     Document Type: Review

References (160)

1. Susser M., and Stein Z. Civilisation and peptic ulcer. Lancet 279 (1962) 116-119
2. Sonnenberg A. Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales. Int J Epidemiol 35 (2006) 1090-1097
3. Warren J.R., and Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 321 (1983) 1273-1275
4. Marshall B.J., and Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 323 (1984) 1311-1315
5. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 272 (1994) 65-69
6. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
7. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
8. Rodriguez L.G., and Barreales T.L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 (2007) 498-506
9. Malfertheiner P., Dent J., Zeijlon L., et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease-results from a randomized trial programme. Aliment Pharmacol Ther 16 (2002) 1431-1442
10. Dew M.J. Asymptomatic peptic ulcer disease. Br Med J (Clin Res Ed) 15 (1987) 401
11. Blatchford O., Davidson L.A., Murray W.R., Blatchford M., and Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 315 (1997) 510-514
12. Rockall T.A., Logan R.F., Devlin H.B., and Northfield T.C. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 311 (1995) 222-226
13. Longstreth G.F. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 90 (1995) 206-210
14. Gisbert J.P., and Pajares J.M. Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 8 (2003) 159-167
15. Gustavsson S. Peptic ulcer disease, complications. In: Gustavsson S., Kumar D., and Graham D.Y. (Eds). The stomach (1992), Churchill Livingstone, Edinburgh, London, Madrid, Melbourne, New York, Tokyo 266-277
16. McColl K. Should non-invasive Helicobacter pylori testing replace endoscopy in investigation of dyspepsia?. Helicobacter 5 (2000) S11-S15
17. McColl K., Murray L.S., Gillen D., et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management for dyspepsia. BMJ 324 (2002) 999-1002
18. Davenport H.W. Salicylate damage to the gastric mucosal barrier. N Engl J Med 276 (1967) 1307-1312
19. Flemström G., and Turnberg L.A. Gastroduodenal defence mechanisms. In: Isenberg J.I., and Johansson C. (Eds). Clinics in Gastroenterology. 13th edn. (1984), WB Saunders Company, London, Philadelphia, Toronto 327-354
20. Grossman M.I. Abnormalities of acid secretion in patients with duodenal ulcer. Gastroenterology 75 (1978) 524-526
21. Rosenstock S., Jorgensen T., Bonnevie O., and Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 52 (2003) 186-193
22. Kurata J.H., and Haile B.M. Epidemiology of peptic ulcer disease. In: Isenberg J.I., and Johansson C. (Eds). Clinics in Gastroenterology. 13th edn. (1984), WB Saunders Company, London, Philadelphia, Toronto 289-307
23. Kato I., Nomura A.M., Stemmermann G.N., and Chyou P.H. A prospective study of gastric and duodenal ulcer and its relation to smoking, alcohol, and diet. Am J Epidemiol 135 (1992) 521-530
24. Peters M.N., and Richardson C.T. Stressful life events, acid hypersecretion, and ulcer disease. Gastroenterology 84 (1983) 114-119
25. Medalie J.H., Stange K.C., Zyzanski S.J., and Goldbourt U. The importance of biopsychosocial factors in the development of duodenal ulcer in a cohort of middle-aged men. Am J Epidemiol 136 (1992) 1280-1287
26. Levenstein S. Bellyaching in these pages: upper gastrointestinal disorders in psychosomatic medicine. Psychosom Med 64 (2002) 767-772
27. Aoyama N., Kinoshita Y., Fujimoto S., et al. Peptic ulcers after the Hanshin-Awaji earthquake: increased incidence of bleeding gastric ulcers. Am J Gastroenterol 93 (1998) 311-316
28. Alain B.B., and Wang Y.J. Cushing's ulcer in traumatic brain injury. Chin J Traumatol 11 (2008) 114-119
29. Gratrix A.P., Enright S.M., and O'Beirne H.A. A survey of stress ulcer prophylaxis in intensive care units in the UK. Anaesthesia 62 (2007) 421-422
30. Rauws E., and Tytgat G.N.J. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335 (1990) 1233-1235
31. Malfertheiner P., Leodolter A., and Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 119-132
32. Sipponen P. Natural history of gastritis and its relationship to peptic ulcer disease. Digestion 51 suppl 1 (1992) 70-75
33. Malfertheiner P. H pylori: its disease and management. In: Weinstein W.M., Hawkey C., and Bosch J. (Eds). Clinical Gastroenterology and Hepatology (2005), Elsevier Mosby, London 193-206
34. Schultze V., Hackelsberger A., Gunther T., Miehlke S., Roessner A., and Malfertheiner P. Differing patterns of Helicobacter pylori gastritis in patients with duodenal, prepyloric, and gastric ulcer disease. Scand J Gastroenterol 33 (1998) 137-142
35. McColl K.E., Gillen D., and El-Omar E. The role of gastrin in ulcer pathogenesis. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 13-26
36. Gillen D., el-Omar E.M., Wirz A.A., Ardill J.E., and McColl K.E. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 114 (1998) 50-57
37. Kuipers E.J., Uyterlinde A.M., Pena A.S., et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for longterm safety. Am J Gastroenterology 90 (1995) 1401-1406
38. Moss S.F., Calam J., Legon S., Bishop A.E., and Polak J.M. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340 (1992) 930-932
39. Odum L., Petersen H.D., Andersen I.B., Hansen B.F., and Rehfeld J.F. Gastrin and somatostatin in Helicobacter pylori infected antral mucosa. Gut 35 (1994) 615-618
40. Graham D.Y., Go M.F., Lew G.M., Genta R.M., and Rehfeld J.F. Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol 28 (1993) 690-694
41. El-Omar E.M., Penman I.D., Ardill J.E., Chittajallu R.S., Howie C., and McColl K.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 (1995) 681-691
42. Olbe L., Hamlet A., Dalenback J., and Fandriks L. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 110 (1996) 1386-1394
43. McColl K.E., Fullarton G.M., Chittajalu R., et al. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 26 (1991) 339-346
44. El-Omar E., Penman I., Dorrian C.A., Ardill J.E., and McColl K.E. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 34 (1993) 1060-1065
45. Khulusi S., Badve S., Patel P., et al. Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 110 (1996) 452-458
46. Harris A.W., Gummett P.A., Walker M.M., Misiewicz J.J., and Baron J.H. Relation between gastric acid output, Helicobacter pylori, and gastric metaplasia in the duodenal bulb. Gut 39 (1996) 513-520
47. Crabtree J.E., Peichl P., Wyatt J.I., Stachl U., and Lindley I.J. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 37 (1993) 65-70
48. Crowe S.E., Alvarez L., Dytoc M., et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 108 (1995) 65-74
49. Dixon M.F. Patterns of inflammation linked to ulcer disease. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 27-40
50. Karttunen R. Blood lymphocyte proliferation, cytokine secretion and appearance of T cells with activation surface markers in cultures with Helicobacter pylori. Comparison of the responses of subjects with and without antibodies to H pylori. Clin Exp Immunol 83 (1991) 396-400
51. Robinson K., Kenefeck R., Pidgeon E.L., et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 57 (2008) 1375-1385
52. Rosam A.C., Wallace J.L., and Whittle B.J. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 319 (1986) 54-56
53. Smoot D.T., Mobley H.L., Chippendale G.R., Lewison J.F., and Resau J.H. Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect Immun 58 (1990) 1992-1994
54. Goggin P.M., Marrero J.M., Spychal R.T., Jackson P.A., Corbishley C.M., and Northfield T.C. Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication. Gastroenterology 103 (1992) 1486-1490
55. Hills B.A. Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it. Gut 34 (1993) 588-593
56. Mauch F., Bode G., Ditschuneit H., and Malfertheiner P. Demonstration of a phospholipid-rich zone in the human gastric epithelium damaged by Helicobacter pylori. Gastroenterology 105 (1993) 1698-1704
57. Figura N., Guglielmetti P., Rossolini A., et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 27 (1989) 225-226
58. Atherton J.C., Cao P., Peek Jr. R.M., Tummuru M.K., Blaser M.J., and Cover T.L. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 270 (1995) 17771-17777
59. Atherton J.C. The clinical relevance of strain types of Helicobacter pylori. Gut 40 (1997) 701-703
60. Censini S., Lange C., Xiang Z., et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 93 (1996) 14648-14653
61. Van Doorn L.J., Figueiredo C., Sanna R., et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 115 (1998) 58-66
62. Peek Jr. R.M., Miller G.G., Tham K.T., et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 73 (1995) 760-770
63. Gerhard M., Lehn N., Neumayer N., et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 96 (1999) 12778-12783
64. Yamaoka Y., Kikuchi S., el-Zimaity H.M., Gutierrez O., Osato M.S., and Graham D.Y. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 123 (2002) 414-424
65. Malaty H.M., Engstrand L., Pedersen N.L., and Graham D.Y. Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med 120 (1994) 982-986
66. Cowan W.K. Genetics of duodenal and gastric ulcer. Clin Gastroenterol 2 (1973) 539-546
67. Boren T., Falk P., Roth K.A., Larson G., and Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 262 (1993) 1892-1895
68. Hofner P., Gyulai Z., Kiss Z.F., et al. Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. Helicobacter 12 (2007) 124-131
69. Chakravorty M., Ghosh A., Choudhury A., Santra A., Hembrum J., and Roychoudhury S. Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 27 (2006) 411-419
70. Azuma T., Konishi J., Tanaka Y., et al. Contribution of HLA-DQA gene to host's response against Helicobacter pylori. Lancet 343 (1994) 542-543
71. Ohyauchi M., Imatani A., Yonechi M., et al. The polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 54 (2005) 330-335
72. Lind T., Megraud F., Unge P., et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116 (1999) 248-253
73. Malfertheiner P., Bayerdorffer E., Diete U., et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 13 (1999) 703-712
74. Hosking S.W., Ling T.K.W., Chung S.C.S., et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343 (1994) 508-510
75. Graham D.Y., Hepps K.S., Ramirez F.C., Lew G.M., and Saeed Z.A. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28 (1993) 939-942
76. Rokkas T., Karameris A., Mavrogeorgis A., Rallis E., and Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 41 (1995) 1-4
77. Santander C., Gravalos R.G., Gomez-Cedenilla A., Cantero J., and Pajares J.M. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 91 (1996) 1549-1552
78. Davenport H.W. Gastric mucosal hemorrhage in dogs. Effects of acid, aspirin, and alcohol. Gastroenterology 56 (1969) 439-449
79. Lichtenberger L.M., Wang Z.M., Romero J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1 (1995) 154-158
80. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol Rev 88 (2008) 1547-1565
81. Lanas A., Baron J.A., Sandler R.S., et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132 (2007) 490-497
82. Wallace J.L., Keenan C.M., and Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 259 (1990) G462-G467
83. Fiorucci S., Distrutti E., and Santucci L. NSAIDs, Coxinbs CINOD and H2S-releasing NSAIDs, what lies beyond the horizon?. Dig Liver Dis 39 (2007) 1043-1051
84. Wallace J.L., and McKnight G.W. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 99 (1990) 295-304
85. Green Jr. F.W., Kaplan M.M., Curtis L.E., and Levine P.H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 74 (1978) 38-43
86. Schmassmann A., Tarnawski A., Peskar B.M., Varga L., Flogerzi B., and Halter F. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol 268 (1995) G276-G285
87. Langman M.J.S., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 1075-1078
88. Rodriguez L.G., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
89. Papatheodoridis G.V., Sougioultzis S., and Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 4 (2006) 130-142
90. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
91. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
92. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
93. Piper J.M., Ray W.A., Daugherty J.R., and Griffin M.R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
94. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 (2002) 1006-1012
95. Chan F.K.L., Sung J., Chung S.C.S., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350 (1997) 975-979
96. Chan F.K.L., To K.F., Wu J., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (2002) 9-13
97. Vergara M., Catalan M., Gisbert J.P., and Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 (2005) 1411-1418
98. Leontiadis G.I., Sreedharan A., Dorward S., et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 11 (2007) iii-iiv 1-164.
99. Labenz J., Blum A.L., Bolten W.W., et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 51 (2002) 329-335
100. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
101. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
102. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., and Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
103. Hallas J., Dall M., Andries A., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 (2006) 726-732
104. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
105. Laine L., Maller E.S., Yu C., Quan H., and Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127 (2004) 395-402
106. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
107. Lanas A., and Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 23 (2007) 163-173
108. Lanza F.L., Chan F.K., Quigley E.M., and Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104 (2009) 728-738
109. Schwartz K. Über penetrierende Magen- und Jejunalgeschwüre. Beitr Klin Chir 67 (1910) 96-128
110. In: Collen M.J., and Benjamin S.B. (Eds). Pharmacology of peptic ulcer disease (1991), Springer-Verlag, Berlin Heidelberg
111. Bianchi-Porro G., and Lazzaroni M. Peptic ulcer-medical treatment. In: Gustavsson S., Kumar D., and Graham D.Y. (Eds). The stomach (1992), Churchill Livingstone, Edinburgh, London, Madrid, Melbourne, New York, Tokyo 246-265
112. Fellenius E., Berglindh T., Sachs G., et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature 290 (1981) 159-161
113. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
114. Banerjee S., El-Omar E., Mowat A., et al. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology 110 (1996) 717-724
115. Leodolter A., Kulig M., Brasch H., Meyer-Sabellek W., Willich S.N., and Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 15 (2001) 1949-1958
116. Tulassay Z., Stolte M., Sjolund M., et al. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 20 (2008) 526-536
117. Chey W.D., and Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102 (2007) 1808-1825
118. Fuccio L., Minardi M.E., Zagari R.M., Grilli D., Magrini N., and Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 147 (2007) 553-562
119. Fischbach L., and Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26 (2007) 343-357
120. Jafri N.S., Hornung C.A., and Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148 (2008) 923-931
121. Sanchez-Delgado J., Calvet X., Bujanda L., Gisbert J.P., Tito L., and Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 103 (2008) 2220-2223
122. Gisbert J.P., and Pajares J.M. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 16 (2002) 1047-1057
123. Realdi G., Dore M.P., Piana A., et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 4 (1999) 106-112
124. Lamouliatte H., Megraud F., Delchier J.C., et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 18 (2003) 791-797
125. Gisbert J.P., and Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23 (2006) 35-44
126. Saad R.J., Schoenfeld P., Kim H.M., and Chey W.D. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101 (2006) 488-496
127. Qasim A., Sebastian S., Thornton O., et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 21 (2005) 91-96
128. Bago J., Pevec B., Tomic M., Marusic M., Bakula V., and Bago P. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 121 (2009) 1-2
129. Lancaster-Smith M.J., Jaderberg M.E., and Jackson D.A. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 32 (1991) 252-255
130. Yeomans N.D., Svedberg L.E., and Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?. Int J Clin Pract 60 (2006) 1401-1407
131. Goldstein J.L., Johanson J.F., Hawkey C.J., Suchower L.J., and Brown K.A. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy-a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 26 (2007) 1101-1111
132. Chan F.K., Sung J.J., Suen R., et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 12 (1998) 1201-1205
133. Targownik L.E., Metge C.J., Leung S., and Chateau D.G. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 134 (2008) 937-944
134. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretorydrugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
135. Ray W.A., Chung C.P., Stein C.M., et al. Risk of peptic ulcer hospitalizations in users of NSAIDs within gastroprotective therapy versus coxibs. Gastroenterology 133 (2007) 790-798
136. Rostom A., Muir K., Dube C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5 (2007) 818-828
137. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
138. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
139. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
140. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 370 (2007) 2138-2151
141. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
142. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 40 (2002) 1366-1374
143. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
144. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
145. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52 (2008) 1502-1517
146. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
147. Juurlink D.N., Gomes T., Ko D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 (2009) 713-718
148. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
149. McColl K.E. Helicobacter pylori-negative ulcer disease. J Gastroenterol 35 suppl 12 (2000) 47-50
150. Xia H.H., Wong B.C., Wong K.W., et al. Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther 15 (2001) 1875-1882
151. Gisbert J.P., Blanco M., Mateos J.M., et al. H pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 44 (1999) 2295-2302
152. Quan C., and Talley N.J. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 97 (2002) 2950-2961
153. El-Nujumi A., Hilditch T.E., Williams C., and McColl K.E. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. Eur J Gastroenterol Hepatol 10 (1998) 759-764
154. Hirschowitz B.I. Intractable peptic ulceration due to aspirin abuse in patients who have not had gastric surgery. Gastroenterology 112 (1997) A962
155. Goddard A.F., Logan R.P.H., Atherton J.C., Jenkins D., and Spiller R.C. Healing of duodenal ulcer after eradication of Helicobacter heilmannii. Lancet 349 (1997) 1815-1816
156. Streitparth F., Pech M., Bohmig M., et al. In vivo assessment of the gastric mucosal tolerance dose after single fraction, small volume irradiation of liver malignancies by computed tomography-guided, high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1479-1486
157. Gillen D., Wirz A.A., Ardill J.E., and McColl K.E. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116 (1999) 239-247
158. Verdu E.F., Armstrong D., Fraser R., et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36 (1995) 539-543
159. Kahn J.M., Doctor J.N., and Rubenfeld G.D. Stress ulcer prophylaxis in mechanically ventilated patients: integrating evidence and judgment using a decision analysis. Intensive Care Med 32 (2006) 1151-1158
160. Heidelbaugh J.J., and Inadomi J.M. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 101 (2006) 2200-2205